SC-0011

N/A

Report date: 2024/04/18 16:34:33
NME

Base Information

Drug NameSC-0011
Drug Alias NameSC-0011
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 1 antagonistsFibroblast growth factor receptor 2 antagonistsFibroblast growth factor receptor 3 antagonists +[5] 
TargetsFibroblast growth factor receptor 1Fibroblast growth factor receptor 2Fibroblast growth factor receptor 3 +[5] 
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShijiazhuang Zhikang Hongren New Drug Development Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesWuxi Hillhouse biomedicine Technology Co LtdShijiazhuang Zhikang Hongren New Drug Development Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsEsophageal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A